Bio-Techne Corporation (TECH)

Bio-Techne's stock price has been impacted by several events in the past six months. In early May 2026, shares declined over 16% after Q3 fiscal 2026 results missed revenue and EPS expectations. Organic revenue was down 2% year-over-year due to softer Protein Sciences demand and softness in emerging biotech spending. Management guided for flat organic growth in Q4 fiscal 2026, citing cell therapy headwinds. CFRA downgraded the stock to Sell, and Wells Fargo maintained its Overweight rating but cut its price target. Prior to the earnings report, the stock had surged with above-average volume. The stock's 52-week range has been between $45.12 and $72.16.

Demand for Bio-Techne's products and services is influenced by research funding levels, diagnostics adoption, and biotech innovation cycles rather than strict calendar seasonality. The company benefits from recurring revenue streams due to repeat purchases. Bio-Techne is vulnerable to fluctuations in research funding cycles and macroeconomic conditions. In Q3 fiscal 2026, the company experienced softer Protein Sciences demand and continued softness in emerging biotech spending. There is a recognized timing lag of typically two to three quarters between funding and spending by biotech customers. Bio-Techne anticipates a meaningful uptick in growth not occurring until the first half of its fiscal year 2027.

Bio-Techne Corporation is a global life sciences company focused on developing, manufacturing, and supplying reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing markets. Their core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions, and automated protein analysis systems. In April 2026, Bio-Techne streamlined its portfolio from ten brands to three: R&D Systems, Bio-Techne Spatial Biology, and Bio-Techne Diagnostics. The company operates through two segments: Protein Sciences (75% of revenue) and Diagnostics and Genomics (25%).

Bio-Techne, headquartered in Minneapolis, Minnesota, serves customers across North America, Europe, and the Asia-Pacific region through direct sales, distributors, and strategic partnerships. The company has a global presence with manufacturing sites, R&D centers, and customer support offices. Approximately 55% of its revenue comes from the United States, with 20% from Europe, the Middle East, and Africa, 5% from the UK, and 15% from Asia-Pacific. Bio-Techne operates in 34 locations worldwide and employs around 3,100 people.

Bio-Techne has a strong brand reputation, recognized for its scientific rigor and quality, earning multiple honors, including CiteAb Researchers' Choice and Innovation Awards. Its tools are noted for significantly impacting life science research by making complex analysis more accessible and reliable. The company's technologies played critical roles in patient monitoring and accelerating vaccine development during the COVID-19 pandemic. In April 2026, Bio-Techne announced a strategic brand alignment to streamline its portfolio. Forbes has also recognized Bio-Techne in 2026 as #299 for America's Best Employers For Company Culture, #264 for America's Best Midsize Employers, and #76 for America's Dream Employers in the Drugs & Biotechnology category.

Bio-Techne's shareholder base is primarily institutional, with institutional ownership exceeding retail stakes. As of early 2026, institutional shareholders own approximately 110.07% of the company, while insiders hold about 2.50%. Key institutional owners include The Vanguard Group, BlackRock Institutional Trust Company, and State Street Investment Management. Other significant shareholders include Morgan Stanley, Wellington Management Group Llp, and Geode Capital Management. Insider ownership is generally under 5%.